BooDog, Are you serious with your RZLT comparison??? First off the RZLT deal is not a license deal with Big Pharma. It is a Private Placement deal which in no way should be compared to a license deal. The RZLT deal is dilutive and could be compared to an MFO funding deal but certainly not what we are expecting or what Bertolino stated in today's PR :

“We are active in advanced discussions with a variety of pharmaceuticals companies. Our goal remains to secure a partner for advanced clinical development of Brilacidin as a new therapeutic for Oral Mucositis and Inflammatory Bowel Disease. At that time, we intend to focus our resources on the next stages of development for Brilacidin, notably dermatologic indications, and Kevetrin as a novel anti-cancer agent to build upon the completed studies.”.

Does the above sound like a dilutive funding deal ? Ending your BS post with a "Leo would state much better terms" doesn't cut it. Hopefully it was an honest mistake of not doing diligence and not a case of soft bashing.